Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 25, 2010
Reporting Period: Single event date (October 25, 2010)
This filing serves as a Regulation FD disclosure to announce upcoming presentations by the Company's President and CEO, Dr. David Aviezer, at two major industry conferences.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
No material financial changes or operational updates are reported in this filing. The document solely announces scheduled corporate communications.
Guidance, Outlook, and Management Commentary
Upcoming Presentations:
- Oppenheimer 21st Annual Healthcare Conference: November 2, 2012, at 12:00 PM ET, Waldorf Astoria Hotel, New York, NY.
- World Orphan Drug Congress 2010: November 30, 2010, at 9:10 AM CEST, Crown Plaza Hotel, Geneva, Switzerland.
Dr. David Aviezer, President and CEO, will present at both events. An audio webcast of the Oppenheimer presentation will be available on the Company's website.
Risks and Contingencies:The filing explicitly states that the information provided is not "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. It is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the date and time of the Oppenheimer 21st Annual Healthcare Conference presentation (November 2, 2010).
- Confirm the availability of the audio webcast on the Company's official website (www.protalix.com).
- Review the full text of the press release furnished as Exhibit 99.1 for specific details on the presentation content.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.